Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/5-MeO-DMT/Tobacco/Nicotine Use Disorder (TUD)

5-MeO-DMT for Tobacco/Nicotine Use Disorder (TUD)

2 papers and 0 clinical trials exploring 5-meo-dmt as a treatment for tobacco/nicotine use disorder (tud).

CompoundTryptamine

5-MeO-DMT

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

Full 5-MeO-DMT profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

2 papers
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Open Accessindividual

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

This naturalistic study (n=20) found that the mystical experience (MEQ) of smoking 5-MeO-DMT was comparable to 30mg/70kg of psilocybin (but not 20mg/70kg) from an earlier study.

Published
December 6, 2018
Journal
Frontiers in Psychology
Authors
Barsuglia, J. P., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A-M., Peterson, K., Polanco, M., Grant, R.

Clinical Trials

0 trials

No clinical trials have been tagged with both 5-MeO-DMT and Tobacco/Nicotine Use Disorder (TUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 5-MeO-DMT papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full 5-MeO-DMT profile Full Tobacco/Nicotine Use Disorder (TUD) profile